Health
The Health Care Economy's Surprising Dynamics: Employment, Humira Biosimilars, and Skyrizi's Rise
The U.S. health care industry's $5.3 trillion footprint is now so large it has become the primary driver preventing workforce contraction. Meanwhile, the biosimilar competition reshaping the Humira market reveals unexpected dynamics as Skyrizi emerges as a dominant force in immunology.
Key Takeaways
- U.S. workforce would have contracted without the $5.3 trillion health care industry's continued job growth
- Humira biosimilar adoption is slower than predicted due to rebate structures and physician prescribing inertia
- Skyrizi is capturing market volume from both Humira and competitors as AbbVie's internal succession strategy
- Three-way competition between branded Humira, biosimilars, and Skyrizi defies simple cost-reduction narratives
- Health care's growing economic footprint makes drug pricing and employment trends into macroeconomic events
DE
DT Editorial AI··via statnews.com